Skip to main content
OpenTrials
Completed

NCT Number: NCT06073496

The Effectiveness of Electroacupuncture and Standard Therapy Compared to Standard Therapy in Gynecological Cancer Pain

Gynecological cancer is cancer that starts in the female reproductive organs. Pain in gynecological cancer can be caused by an underlying malignancy or surgical procedure as well as chronic pain associated with malignancy and sequelae of the therapy given. Gynecological cancer patients often experience moderate to severe pain and use higher levels of opioids than patients diagnosed with other cancers. More than two thirds of patients with advanced cancer experience severe pain and up to half of these patients report that their pain is not well controlled. This study aims to analyze the effectiveness of electroacupuncture plus standard therapy on pain intensity (VAS score), changes in analgesic dose, and quality of life (QLQ C-30 EORTC score) in patients with gynecological cancer pain compared to standard therapy alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Fatmawati Hospital, Jakarta, DKI Jakarta, Indonesia

Loading trial locations.

About this study

This study was conducted using single blinded randomized control clinical trial, design in 58 patients diagnosed with gynecological cancer, aged 18 to 65 years, who experienced cancer pain, with VAS ≥ 4, pain caused by a tumor, before or while undergoing a therapeutic process (radiation therapy, chemotherapy, or post surgery), side effects or due to the toxicity of cancer treatment, willing to take part in this study and sign informed consent who were randomized into 2 groups, namely group I electroacupuncture with standard therapy and group 2 standard therapy, the acupuncture points used were LI4, PC6, ST36, SP6 and LR3, after the acupuncture needle was inserted, the needle was connected to the electrosimulator. The outputs assessed were pain intensity using the VAS, changes in analgesic dose, and quality of life with the EORTC QLQ C-30 questionnaire, which was assessed on the day before starting therapy, the first day, the second day, the third day, the fifth day and the seventh day.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female 18 to 65 years old
  • Gynecocal cancer with pain ≥ 4 acording Visual Analog scale and receive analgetic medicine
  • The pain cause by
  • direct from cancer
  • Treatment proces surgery, radiotherapy, chemotherapy, paliatif treatment, supportive treatment
  • Adverse reaction form treatment and intoxication

Exclusion criteria

  • Emergency case patient with hemodynamic instable
  • Patient with uncooperative behavior because ith serious psychological disorders, no currently undergoing psychiatric treatment, aggressive behavior, that not allowed for acupuncture.
  • Patients with blood clotting disorders, with platelets <50.000 and in neutropenic condition with <1000 neutrophils.
  • The patient has an allergy to stainless steel acupuncture needles. Wounds at the acupuncture point puncture sites, skin infections in the ears. On patients with eczema on the ears, external otitis or psoriasis.
  • There is a tumor in the area that will be stabbed and stimulated in the stomach pregnant women, close to the heart, or in the area of the carotid sinus lymphedema, insertion into the prosthesis.
  • Patients with heart rhythm disorders. The patient uses a pace maker.

Treatment and study plan

electroacupuncture

Other

Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator

Primary outcomes

  1. Pain severity with Visual Analog Scale

    Time frame: Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

    Rating scale for measuring pain, where the minimum value is 0 = no pain, and the maximum value is 100 = severe pain. A higher scale means worse outcomes.

Secondary outcomes

  1. European Organisation for Research and Treatment of Cancer Quality of Life C30

    Time frame: before treatment and 7 day after treatment

    A Quesionaire for measuring quality of Life

  2. Analgetic Usage in dosage and frequency

    Time frame: Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

    by assessing drug dose reductions and frequency before and after

Sponsors and collaborators

Lead sponsor

Indonesia University

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 10, 2023
Registry last updated
Jan 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.